ライフサイエンスコーパス: metered dose inhaler

1 ons twice daily for 52 weeks via pressurised metered-dose inhaler.

2 uticasone administered through a pressurized metered-dose inhaler.

3 Patients received IB by metered-dose inhaler (40mug per dose) with a spacer thre

4 fety of fluticasone-salmeterol delivered via metered-dose inhaler (Advair HFA) versus dry powder inha

5 Metered-dose inhalers are associated with substantially

6 hort-acting beta-agonist (SABA) delivered by metered-dose inhaler as first-line therapy for younger a

7 (100 mug, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (alb

8 Ten metered-dose inhaler canisters were used to administer 2

9 ssation counseling and the prescription of a metered-dose inhaler containing either ipratropium bromi

10 Metered-dose inhalers employ propellants to produce phar

11 ients receiving fluticasone-salmeterol via a metered-dose inhaler (exposure) were compared to those r

12 aerosols from the corresponding pressurized metered-dose inhaler formulations (pMDIs) that have exce

13 Given the added climate impact of metered dose inhalers, health systems seeking to decreas

14 Bronchodilator administration by metered-dose inhaler is becoming the preferred therapy f

15 twice daily, delivered through a combination metered dose inhaler (MDI), with one extra actuation as

16 s used to assess the use of beta-agonists by metered dose inhaler (MDI).

17 se albuterol (15-microg dose) and 200 microg metered-dose inhaler (MDI) albuterol.

18 on from a chlorofluorocarbon (CFC)-propelled metered-dose inhaler (MDI) during mechanical ventilation

19 sed the safety and efficacy of a ciclesonide metered-dose inhaler (MDI) for treating nonhospitalized

20 Successful bronchodilator therapy with a metered-dose inhaler (MDI) in intubated, mechanically ve

21 tion after inhaling racemic albuterol with a metered-dose inhaler (MDI) is not known.

22 lower asthma medication knowledge and worse metered-dose inhaler (MDI) technique, the relationship b

23 he efficiency of aerosol administration by a metered-dose inhaler (MDI), we measured serum albuterol

24 aler [DPI], fluticasone DPI, fluticasone-CFC metered dose inhaler [MDI], flunisolide-CFC, and triamci

25 Aerosols from metered dose inhalers (MDIs) with these propellants beco

26 ital admissions, quality of life, and use of metered dose inhalers (MDIs), may be related to this dif

27 us He-O2 mixtures on albuterol delivery from metered-dose inhalers (MDIs) and jet nebulizers in an in

28 In nonintubated patients, metered-dose inhalers (MDIs) are accepted as the most co

29 etion of stratospheric ozone, CFC-containing metered-dose inhalers (MDIs) such as Ventolin and Proven

30 er administration of 180 microg albuterol by metered dose inhaler, mean Qaw increased by 83 +/- 26% i

31 ed for by spontaneous nebulizers (p = .001), metered dose inhalers (p = .01), and pulse oximetry (p =

32 The pressurised metered-dose inhaler (pMDI) is still the most frequently

33 rol with a budesonide/formoterol pressurized metered-dose inhaler (pMDI) versus budesonide over 1 yea

34 5% of global GHG emissions, with pressurised metered-dose inhalers (pMDIs) a significant contributor

35 mulary transition from budesonide-formoterol metered-dose inhaler to fluticasone-salmeterol dry-powde

36 Transitioning from metered-dose inhalers to propellant-free dry-powder inha

37 Electronic sensors fitted on metered dose inhalers tracked 5,660 rescue inhaler use e

38 Treatment with budesonide-formoterol metered-dose inhaler vs fluticasone-salmeterol dry-powde

39 Use of fluticasone-salmeterol via metered-dose inhaler was associated with a similar hazar

40 buterol (n = 28) or placebo (n = 13) using a metered-dose inhaler with a spacer.

41 er treatment with 400 mug of salbutamol in a metered-dose inhaler with or without a spacer, variabili